← Patent-cliff monitor Loss of exclusivity October 2036 latest FDA-listed patent expiry
Company Novartis → View the full company profile on CliffBio Drug detail Brand name KISQALI FEMARA CO-PACK (COPACKAGED) Active ingredient LETROZOLE; RIBOCICLIB SUCCINATE Strength 2.5MG;EQ 200MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval May 2017 Marketing status RX
Listed patents Patent Expires Type 12064434*PED October 2036 — 10799506*PED October 2036 — 12419894*PED October 2036 — 12064434 April 2036 product 12419894 April 2036 product 10799506 April 2036 product 12544380*PED February 2035 — 12544380 August 2034 use U-3998 9868739*PED May 2032 — 9193732*PED May 2032 — 9193732 November 2031 substance, product 9868739 November 2031 use U-3264 8415355*PED September 2031 — 8415355 March 2031 substance, product 8685980*PED November 2030 — 8962630*PED June 2030 — 8685980 May 2030 substance, product 9416136*PED February 2030 — 8962630 December 2029 use U-3264 9416136 August 2029 use U-3264 8324225*PED December 2028 — 8324225 June 2028 substance, product
Regulatory exclusivity Code Expires PED March 2028 I-951 September 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.